IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

BACKGROUND: Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitumor activity. The objective of this trial was to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Timothy A, Bessudo, Alberto, Hamilton, Erika, Sachdev, Jasgit, Patel, Manish R, Rodon, Jordi, Evilevitch, Lena, Duncan, Meghan, Guo, Wei, Kumar, Sujatha, Lu, Sharon, Dezube, Bruce J, Gabrail, Nashat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948406/
https://www.ncbi.nlm.nih.gov/pubmed/35332062
http://dx.doi.org/10.1136/jitc-2021-003924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948406/
https://www.ncbi.nlm.nih.gov/pubmed/35332062
http://dx.doi.org/10.1136/jitc-2021-003924

Ejemplares similares